Plasma Vitamin E and the Risk of First Stroke in Hypertensive Patients: A Nested Case-Control Study

Yun Song¹²‡, Jingyi Li³⁷, Lishun Liu⁴⁷, Richard Xu⁶, Ziyi Zhou⁴, Benjamin Xu⁶, Tengfei Lin¹⁷, Ping Chen⁷, Huan Li⁸⁹, Youbao Li⁸⁹, Chengzhang Liu¹², Xiaowei Huang¹², Binyan Wang²,¹¹, Yan Zhang¹³, Jianping Li¹³, Yong Huo¹³, Fazheng Ren¹, Xiping Xu¹,⁸⁹,¹⁰, Hao Zhang¹* and Xianhui Qin⁸⁹,¹⁰‡

¹ Key Laboratory of Precision Nutrition and Food Quality, Department of Nutrition and Health, College of Food Sciences and Nutritional Engineering, China Agricultural University, Beijing, China, ² Institute of Biomedicine, Anhui Medical University, Hefei, China, ³ State Key Laboratory of Natural Medicines, Research Center of Biostatistics and Computational Pharmacy, China Pharmaceutical University, Nanjing, China, ⁴ Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, China, ⁵ Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States, ⁶ Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, United States, ⁷ College of Pharmacy, Jinan University, Guangzhou, China, ⁸ National Clinical Research Study Center for Kidney Disease, Southern Medical University, Guangzhou, China, ⁹ The State Key Laboratory for Organ Failure Research, Southern Medical University, Guangzhou, China, ¹⁰ Renal Division, Nanfang Hospital, Southern Medical University, Guangzhou, China, ¹¹ Department of Scientific Research, Shenzhen Evergreen Medical Institute, Shenzhen, China, ¹² Department of Cardiology, Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹³ Department of Cardiology, Peking University First Hospital, Beijing, China

Background: The association between plasma vitamin E levels and first stroke risk in men and women remains unclear.

Objective: We aimed to examine the prospective association between plasma vitamin E and first stroke, and evaluate the effect modifiers for the association, among hypertensive patients.

Design: The study sample was drawn from the China Stroke Primary Prevention Trial (CSPPT), which randomized a total of 20,702 hypertensive patients to a double-blind, daily treatment with either 10 mg enalapril and 0.8 mg folic acid or 10 mg enalapril alone. This nested case-control study, including 618 first stroke cases and 618 controls matched for age, sex, treatment group, and study site, was conducted after the completion of the CSPPT.

Results: The median follow-up duration was 4.5 years. Among men, a significantly higher risk of first stroke (adjusted OR, 1.67; 95%CI: 1.01, 2.77) was found for those with plasma vitamin E ≥7.1 µg/mL (≥quartile 1) compared with those with plasma vitamin E < 7.1 µg/mL. Subgroup analyses further showed that the association between vitamin E (≥7.1 µg/mL) and first stroke in men was significantly stronger in non-drinkers (adjusted OR, 2.64; 95%CI: 1.41, 4.96), compared to current drinkers (adjusted OR, 0.84; 95% CI: 0.43, 1.66, P-interaction = 0.008). However, there was no significant association between plasma vitamin E and first stroke in women (P-interaction between sex and plasma vitamin E = 0.048).
**INTRODUCTION**

Stroke is a leading cause of death in China and a major cause of long-term disability worldwide (1). Almost 76% of strokes are first attacks; accordingly, primary prevention is regarded as the best option to reduce the population burden of stroke (2). While many factors, including hypertension, diabetes mellitus, smoking, atrial fibrillation, hyperlipidemia, hyperhomocysteinemia, and alcohol intake have been identified as significant modifiable risk factors of stroke (3), there remains an urgent need to identify additional modifiable risk factors to further lower residual risk of first stroke and to develop safe, inexpensive, and effective primary prevention strategies to halt or reverse the rapidly rising trend of stroke in China and many parts of the world.

Vitamin E is an essential fat-soluble vitamin and is known for its antioxidant property. It is postulated that vitamin E protects against atherogenesis by acting as a scavenger of free radicals with subsequent reduced oxidation of low-density lipoprotein cholesterol, and by enacting several other favorable effects on plaque stability, platelet aggregation, and tendency to thrombosis (4–7). However, results from previous clinical trials of vitamin E supplementation (8, 9) and prospective studies of vitamin E intake (10) have been conflicting, ranging from a protective association, no clear association, to being a risk factor of cardiovascular disease (CVD), in particular, stroke.

A recent meta-analysis of randomized controlled trials reported that vitamin E supplementation had no significant effect on total, fatal or non-fatal stroke, but may offer some benefits in the prevention of ischemic stroke (11). However, prior randomized trials were mostly done in developed countries (11), and have mainly examined the effects of relatively high dose vitamin E supplementation in patients with CVD and/or diabetes, and did not consider the possible modifying effect of baseline plasma levels of vitamin E (12). Moreover, although dietary intake is known to correlate poorly with circulating vitamin levels, particularly vitamins C and E, most of the previous vitamin E studies were based on estimates of dietary vitamin E intake (10, 13, 14) rather than objective biomarker measurements. To date, only a few previous studies had been conducted to evaluate the prospective association between plasma vitamin E and the risk of stroke mortality (15) or ischemic stroke (16), and reported inconsistent findings. At the same time, few previous researches have comprehensively investigated the modifiers in the association between vitamin E and the risk of stroke. As such, the prospective association between circulating vitamin E and first stroke in population without the use of vitamin E supplements remains uncertain.

Furthermore, the issue has not been well-examined in populations with hypertension. This subgroup of the population deserves more attention, not only because it is less studied, but also because it is a subpopulation with a high risk for stroke. To address these significant gaps in knowledge outlined above, we aimed to explore the prospective association between baseline plasma vitamin E levels and the risk of first stroke, and evaluate whether the association can be modified by known risk factors of stroke, among hypertensive patients. We used a nested case-control study design leveraging the unique strength and resources of China Stroke Primary Prevention Trial (CSPPT) (17), which has high quality baseline and follow-up data and archived biospecimens.

**METHODS**

The parent study (the CSPPT) and the current study were approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (FWA assurance number: FWA00001263). All participants gave prior written informed consent. The data that support the findings of this study will be available from the corresponding authors upon request, after the request is submitted and formally reviewed and approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University.

**Study Design and Participants**

The methods and major results of the CSPPT trial have been reported elsewhere (17–21). Briefly, the CSPPT was a multi-community, randomized, double-blind, controlled trial (17) conducted from May 19, 2008 to August 24, 2013 in 32 communities in Anqing, Anhui province and Lianyungang, Jiangsu province of China. Eligible participants were men and women aged 45–75 years with hypertension, defined as having a seated, resting systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥90 mmHg at both the screening and recruitment visit or taking antihypertensive medication. The major exclusion criteria included history of physician-diagnosed stroke, myocardial infarction (MI), heart failure, post-coronary revascularization, and/or congenital heart disease.

In the CSPPT, a total of 20,702 eligible participants were randomly assigned, in a 1:1 ratio, to one of two treatment groups: a daily oral dose of one tablet containing 10 mg enalapril and 0.8 mg folic acid (the enalapril-folic acid group), or a daily oral dose of one tablet containing only 10 mg enalapril (the enalapril...
only group). Participants were followed up every 3 months. Over a median treatment duration of 4.5 years, a total of 637 incident stroke cases occurred in the CSPPT.

Using data from the CSPPT, we conducted a nested case-control study. We identified all the participants from the CSPPT baseline participants who did not develop stroke during the follow-up as eligible controls. We then randomly matched eligible controls with first stroke cases by age (±1 year), sex, treatment group, and study sites in a 1:1 ratio. That is, the cumulative-incidence’ sampling scheme was used. The initial sample consisted of 637 incident cases and 637 matched controls. Of the 1,274 selected cases or controls, 10 cases and 9 controls had missing values of vitamin E; as a result, 19 case/control pairs were removed either because of missing values of vitamin E or because of unpaired cases or controls. The final analyses included 618 matched case-control pairs (Figure 1).

Assessment of Covariates
Baseline data collection was conducted by trained research staff according to a standard operating procedure. Each participant was interviewed using a standardized questionnaire designed specifically for this study. Current smoking was defined as having smoked at least 1 cigarette per day or ≥18 packs in the last year. Current drinking was defined as drinking alcohol at least 2 times per week in the last year.

Anthropometric measurements, including height, weight, and waist circumference, were taken using a standard operating procedure. Height was measured without shoes to the nearest 0.1 cm on a portable stadiometer. Weight was measured in light indoor clothing without shoes to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight (kilograms)/height (meters) squared.

Seated BP was measured by trained research staff using a mercury manometer after the participants had rested for 10 min, following the standard method and with appropriately sized cuffs. Triplicate measurements on the same arm were taken, with at least 2 min between readings. The average of the three independent measures was used in the analyses.

Outcomes Assessment
As detailed in an earlier report, the primary outcome was a first non-fatal or fatal stroke (ischemic or hemorrhagic), excluding subarachnoid hemorrhage and silent stroke. Secondary outcomes included first ischemic stroke and first hemorrhagic stroke. All the study outcomes were reviewed and adjudicated according to standard criteria by an independent Endpoint Adjudication Committee (17).

Laboratory Assays
Overnight fasting venous blood samples were obtained from each study participant at baseline. Serum folate and vitamin B_{12} were measured by a commercial laboratory using a chemiluminescent immunoassay (New Industrial). Serum creatinine, total homocysteine (tHcy), fasting lipids, and fasting glucose were measured using automatic clinical analyzers (Beckman Coulter) at the core laboratory of the National Clinical Research Center for Kidney Disease, Nanfang Hospital, Guangzhou, China. Plasma vitamin E (alpha-tocopherol), vitamin D_{3} and retinol were measured by liquid chromatography with tandem quadrupole mass spectrometers (LC-MS/MS) in a commercial lab (Beijing DIAN Medical Laboratory, China). Plasma selenium, magnesium, copper, and zinc concentrations were measured by inductively coupled plasma mass spectrometry (ICP-MS) using Thermo Fisher iCAP Q ICP-MS in a commercial lab (Beijing DIAN Medical Laboratory, China).
Statistical Analysis

Baseline characteristics are presented as means ± SDs for continuous variables and proportions for categorical variables. Differences in baseline characteristics between cases and controls by sex were compared using conditional logistic regression for categorical variables and generalized paired t-tests for continuous variables.

Variables that are known as traditional or suspected risk factors for stroke suggested in previous related guidelines were chosen as the covariates in our current study. Odds ratios (ORs) of first stroke and its subtypes were estimated by modeling plasma vitamin E as quartiles (<quartile 1, quartile 1- < quartile 2, quartile 2- < quartile 3, and ≥quartile 3) and as categories (<quartile 1 vs. ≥quartile 1) using conditional logistic regression, without and with adjustment for BMI (continuous), current smoking (yes vs. no), current alcohol drinking (yes vs. no), systolic blood pressure (SBP) at baseline (continuous), fasting blood glucose (continuous), total cholesterol (TC) (continuous), triglycerides (TG) (continuous), high-density lipoprotein cholesterol (HDL-C) (continuous), total homocysteine (tHcy) (continuous), folate (continuous), and estimated glomerular filtration rate (eGFR) (continuous) at baseline. In addition, possible modifications of the association between vitamin E (<quartile 1 vs. ≥quartile 1) and first stroke (total and ischemic) for males were assessed for the following variables: age (<65 vs. ≥65 years) (23), treatment group (enalapril vs. enalapril-folic acid), BMI (<24.1 (median) vs. ≥24.1 kg/m²), baseline SBP (<160 vs. ≥160 mmHg), current smoking status (no, yes), current alcohol drinking status (no, yes), TC (<5.2 vs. ≥5.2 mmol/L), tHcy [<14.6 (median) vs. ≥14.6 µmol/L], and fasting glucose (<6.1 vs. ≥6.1 mmol/L or diabetes) at baseline. Potential interactions were examined by including the interaction terms into the logistic regression models. Of note, ORs of first hemorrhagic stroke in males were positively associated with TC, HDL-C, vitamin B12, folate, retinol, and vitamin D₃ concentrations at baseline (Supplementary Table 2). Similar associations were found in female patients (Supplementary Table 3).

Association Between Vitamin E and First Stroke

The median treatment duration was 4.5 years (IQR, 4.2–4.6 years). As shown in Table 2, when plasma vitamin E was assessed as quartiles in males, compared with <quartile 1 (<7.1 µg/mL), the adjusted ORs (95% CI) were 1.47 (0.83, 2.58), 1.88 (1.03, 3.45), and 1.93 (0.97, 3.84), respectively, for quartile 1- < quartile 2, quartile 2- < quartile 3, and ≥quartile 4 (P for trend = 0.038). Participants in ≥quartile 1 had a significantly higher risk of first stroke (OR, 1.67; 95% CI: 1.01, 2.77) compared with those in <quartile 1 (<7.1 µg/mL). Similar trends were found for first ischemic stroke and first hemorrhagic stroke.

Among male participants, stroke cases and controls had no difference in concomitant medication use during the treatment period (Supplementary Table 4). Moreover, during the treatment period, there was no difference in concomitant medication use among vitamin E quartile concentrations in male participants (Supplementary Table 5). As expected, further adjustments for the use of medications during the treatment period (Supplementary Table 6) did not substantially alter the findings. Moreover, further adjustments for baseline serum vitamin B₁₂, and plasma zinc, copper, retinol, vitamin D₃, selenium, and magnesium (Supplementary Table 7); further adjustments for baseline educational levels and marital status (Supplementary Table 8); or categorizing vitamin E according to quartiles in the total population (Supplementary Table 9), also did not materially change the results.

Nevertheless, no clear association of plasma vitamin E with first stroke or its subtypes was found in females (Table 3). Sex significantly modified the association between plasma vitamin E (<quartile 1 vs. ≥quartile 1) with first stroke (P-interaction = 0.048).

Subgroup Analyses

Among males, stratified analyses were performed to further assess the association between plasma vitamin E (<quartile 1 vs. ≥quartile 1) and the risk of first stroke in various subgroups (Figure 2, Supplementary Table 10). A stronger positive association between vitamin E and first stroke was observed in non-drinkers (adjusted OR, 2.64; 95% CI: 1.41, 4.96) compared to current drinkers (adjusted OR, 0.84; 95% CI: 0.43, 1.66, P-interaction = 0.008).

None of the other variables in males, including age, treatment group, body mass index, baseline SBP, time-averaged SBP, smoking status, total cholesterol, total homocysteine, eGFR,
TABLE 1 | Characteristics of stroke cases and control subjects by sex.

| Characteristics          | Controls (n = 294) | Cases (n = 294) | Controls (n = 324) | Cases (n = 324) |
|--------------------------|-------------------|----------------|-------------------|----------------|
| Vitamin E, µg/mL         | 9.2 (3.6)         | 9.6 (3.5)      | 10.0 (3.5)        | 10.0 (3.5)     |
| Age, years               | 63 (7.1)          | 63 (7.1)       | 61.5 (7.3)        | 61.5 (7.3)     |
| Body mass index, kg/m²   | 24.1 (3.1)        | 24.4 (3.5)     | 25.4 (3.6)        | 25.9 (4.0)     |
| Waist-hip ratio          | 0.9 (0.1)         | 0.9 (0.1)      | 0.9 (0.1)         | 0.9 (0.1)      |
| Current smoking, No. (%) | 151 (51.4)        | 167 (56.8)     | 6 (1.9)           | 18 (5.6)       |
| Current alcohol drinking, No. (%) | 137 (46.6) | 148 (50.3) | 12 (3.7) | 12 (3.7) |
| Enalapril-folic acid, No. (%) | 119 (40.5) | 119 (40.5) | 153 (47.2) | 153 (47.2) |
| Antihypertensive drugs, No. (%) | 127 (43.2) | 146 (49.7) | 157 (48.5) | 175 (54.0) |
| Blood pressure, mmHg     |                  |                |                  |                |
| Baseline SBP             | 166.3 (20.4)      | 176.2 (21.6)   | 169.5 (19.8)      | 177.5 (23.9)   |
| Baseline DBP             | 94.9 (12.4)       | 98.2 (14.0)    | 92.3 (11.5)       | 96.8 (13.1)    |
| Time averaged SBP        | 138.9 (10.7)      | 148.5 (15.7)   | 140 (11.4)        | 149.5 (15.3)   |
| Time averaged DBP        | 82.8 (7.9)        | 87.2 (10.6)    | 81.5 (6.6)        | 86.3 (9.1)     |
| Laboratory results       |                  |                |                  |                |
| Total cholesterol, mmol/L| 5.5 (1.1)         | 5.6 (1.3)      | 5.7 (1.2)         | 5.9 (1.2)      |
| Triglycerides, mmol/L    | 1.5 (0.9)         | 1.5 (0.8)      | 1.7 (1.1)         | 1.8 (1.0)      |
| HDL cholesterol, mmol/L  | 1.4 (0.4)         | 1.4 (0.4)      | 1.3 (0.3)         | 1.3 (0.3)      |
| Total homocysteine, µmol/L| 17.7 (10.6)     | 18.7 (12.2)    | 12.6 (4.4)        | 13.2 (4.9)     |
| Fasting glucose, mmol/L  | 5.8 (1.4)         | 6.1 (2.2)      | 6.0 (1.9)         | 6.4 (2.6)      |
| eGFR, ml/min/1.73 m²     | 90.8 (13.0)       | 89.3 (14.1)    | 92.5 (13.1)       | 92.4 (13.3)    |
| Vitamin B12, pg/mL       | 428 (182.7)       | 403.5 (142.5)  | 409.5 (138.7)     | 421.7 (179.9)  |
| Folate, ng/mL            | 7.8 (4.2)         | 7.3 (3.3)      | 8.8 (3.6)         | 8.6 (3.7)      |
| Zinc, µg/dL              | 109.6 (30.5)      | 109.5 (37.5)   | 110.5 (26.5)      | 114.1 (47.8)   |
| Copper, µg/dL            | 97.4 (20.2)       | 98.8 (19.0)    | 109.0 (20.4)      | 111.9 (20.6)   |
| Retinol, µg/dL           | 80.1 (29.2)       | 77.5 (28.4)    | 64.5 (20.4)       | 62.9 (20.3)    |
| Selenium, µg/dL          | 8.6 (2.0)         | 8.5 (2.1)      | 8.4 (2.1)         | 8.2 (1.9)      |
| Magnesium, mg/L          | 20.3 (2.2)        | 20.3 (2.3)     | 20.5 (2.3)        | 20.6 (2.6)     |
| Vitamin D₃, ng/mL        | 21.4 (8.5)        | 21.0 (7.6)     | 17.6 (7.0)        | 17.6 (7.0)     |

*For continuous variables, values are presented as mean (SD).
DBP, diastolic blood pressure; SBP, systolic blood pressure; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate.

DISCUSSION

In this nested case-control study derived from the CSPPT, using objective measure of plasma vitamin E (alpha-tocopherol) levels, we demonstrated a significant positive association between plasma vitamin E and subsequent risk of first stroke in male hypertensive patients. Furthermore, our subgroup analyses demonstrated that the positive relation of plasma vitamin E with first stroke was more pronounced in male participants who were non-drinkers.

Previous studies have examined the relation of blood vitamin E with mortality risk in non-Chinese population, but the results have been inconclusive (24, 25). Buijsse et al. (24) found that plasma concentrations of α-tocopherol were not associated with all-cause or cause-specific mortality in elderly subjects who participated in a European prospective study. Wright et al. (25) showed that higher serum α-tocopherol levels were related to moderately lower total and cause-specific mortality in older male smokers. However, only a few previous studies (15, 16) have examined the association between blood vitamin E concentrations and the risk of stroke. Nagao et al. (15) found that serum α-tocopherol level was not associated with any type of cardiovascular death in Japanese men; however, in women, it was inversely associated with hemorrhagic stroke mortality. Of note, this study (15) did not have data about incident stroke. At the same time, Hak et al. (16) reported that levels of α-tocopherol were not associated with ischemic stroke in the Physicians’ Health Study, in which about 35% of the participants used multiple vitamins supplements. More importantly, only a part of the

TG, HDL-C, fasting glucose, folate, retinol levels, copper levels, vitamin B₁₂ levels, zinc levels, magnesium levels, selenium levels, and vitamin D₃ levels, showed significant effect modifications on the association between plasma vitamin E and the risk of first stroke (P-interaction > 0.05 for all these stratified variables).
participants had hypertension in the two previous studies, and both of the studies did not account for some important potential confounders, such as eGFR, other nutrients, and mean BP over the follow-up period. Therefore, the findings from the above studies suggested that the association between circulating vitamin E and first stroke in hypertensive population without vitamin E supplements remains uncertain.

Our study offered a chance to evaluate the dose-response relation of plasma vitamin E with first stroke in hypertensive patients by leveraging the well-established CSPPT, a randomized controlled trial. Our study has contributed to several new insights. First, in hypertensive men, there was a significantly positive relationship of plasma vitamin E with incident risk of first stroke. The potential mechanism by which higher vitamin E may increase risk of stroke is still unclear, but it is biologically plausible. In 1981, Roberts had reported that high dosages of vitamin E were associated with thrombophlebitis, hypertension, fatigue, and increased levels of free cholesterol in low-density, and very-low-density lipoproteins (LDL) \(^{26}\). In fact, a series of previous studies found that alpha-tocopherol (alpha-TOH) can act as a pro-oxidant for isolated low-density lipoprotein (LDL) \(^{27–29}\), by reaction of the \(\alpha\)-tocopheroxyl radical with polyunsaturated fatty acid moieties in the lipid \(^{30}\).

Second, this study suggested a possible sex difference. We did not find a significant relationship of vitamin E with first stroke in females. Two possible explanations for this include: (1) estrogen acts to prevent oxidative damage of the endothelium and oxidation of LDL in the atherosclerotic process, which begins

| Vitamin E, µg/mL | Cases/controls | Unadjusted OR (95% CI) | P-value | Adjusted* OR (95% CI) | P-value |
|-----------------|---------------|------------------------|---------|-----------------------|---------|
| First stroke    |               |                        |         |                       |         |
| Per SD increment| 294/294       | 1.16 (0.96, 1.40)       | 0.134   | 1.19 (0.93, 1.54)      | 0.166   |
| Quartiles       |               |                        |         |                       |         |
| Q1 (<7.1)       | 66/81         | Ref.                   |         | Ref.                  |         |
| Q2 (7.1–<8.8)   | 69/78         | 1.12 (0.71, 1.77)       | 0.630   | 1.47 (0.83, 2.58)      | 0.186   |
| Q3 (8.9–<11.3)  | 80/67         | 1.56 (0.95, 2.55)       | 0.077   | 1.88 (1.03, 3.45)      | 0.040   |
| Q4 (≥11.3)      | 79/68         | 1.57 (0.93, 2.67)       | 0.092   | 1.93 (0.97, 3.84)      | 0.060   |
| P for trend     |               | 0.040                  |         | 0.038                 |         |
| Categories      |               |                        |         |                       |         |
| <7.1            | 66/81         | Ref.                   |         | Ref.                  |         |
| ≥7.1            | 228/213       | 1.35 (0.91, 2.00)       | 0.137   | 1.67 (1.01, 2.77)      | 0.046   |
| Ischemic stroke |               |                        |         |                       |         |
| Per SD increment| 244/244       | 1.21 (0.98, 1.50)       | 0.079   | 1.27 (0.94, 1.69)      | 0.115   |
| Quartiles       |               |                        |         |                       |         |
| Q1 (<7.1)       | 54/68         | Ref.                   |         | Ref.                  |         |
| Q2 (7.1–<8.8)   | 59/63         | 1.24 (0.75, 2.05)       | 0.411   | 1.61 (0.86, 3.00)      | 0.137   |
| Q3 (8.8–<11.2)  | 62/60         | 1.38 (0.81, 2.35)       | 0.238   | 1.54 (0.79, 2.99)      | 0.202   |
| Q4 (≥11.2)      | 69/53         | 1.94 (1.07, 3.51)       | 0.028   | 2.39 (1.10, 5.18)      | 0.028   |
| P for trend     |               | 0.029                  |         | 0.046                 |         |
| Categories      |               |                        |         |                       |         |
| <7.1            | 54/68         | Ref.                   |         | Ref.                  |         |
| ≥7.1            | 190/176       | 1.41 (0.91, 2.19)       | 0.124   | 1.67 (0.95, 2.93)      | 0.075   |
| Hemorrhagic stroke |             |                        |         |                       |         |
| Per SD increment| 49/49         | 0.99 (0.66, 1.47)       | 0.948   | 1.07 (0.57, 2.01)      | 0.822   |
| Quartiles       |               |                        |         |                       |         |
| Q1 (<7.7)       | 12/13         | Ref.                   |         | Ref.                  |         |
| Q2 (7.7–<9.4)   | 11/13         | 0.92 (0.30, 2.82)       | 0.879   | 1.74 (0.28, 10.83)     | 0.552   |
| Q3 (9.4–<12.3)  | 15/9          | 1.81 (0.58, 5.64)       | 0.309   | 5.24 (0.82, 33.62)     | 0.081   |
| Q4 (≥12.3)      | 11/14         | 0.85 (0.28, 2.59)       | 0.777   | 1.29 (0.22, 7.42)      | 0.777   |
| P for trend     |               | 0.929                  |         | 0.549                 |         |
| Categories      |               |                        |         |                       |         |
| <7.7            | 12/13         | Ref.                   |         | Ref.                  |         |
| ≥7.7            | 37/26         | 1.11 (0.45, 2.76)       | 0.817   | 2.11 (0.47, 9.53)      | 0.332   |

*Adjusted for body mass index (BMI), smoking status, alcohol drinking, systolic blood pressure (SBP) at baseline, fasting blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), total homocysteine (tHcy), folate, as well as estimated glomerular filtration rate (eGFR) at baseline.
| Vitamin E, μg/mL | Cases/controls | Unadjusted | Adjusted |
|----------------|----------------|------------|----------|
|                | OR (95% CI)    | P-value    | OR (95% CI) | P-value |
| First stroke   |                |            |           |
| Per SD increment | 324/324       | 1.01 (0.84, 1.22) | 0.886 | 0.92 (0.73, 1.15) | 0.455 |
| Quartiles      |                |            |           |
| Q1 (<7.6)      | 80/82          | Ref.       | Ref.      |
| Q2 (7.6–<9.5)  | 75/87          | 0.90 (0.57, 1.42) | 0.662 | 0.84 (0.51, 1.40) | 0.504 |
| Q3 (9.5–<12.0) | 93/69          | 1.39 (0.86, 2.24) | 0.181 | 1.11 (0.63, 1.95) | 0.716 |
| Q4 (≥12.0)     | 76/86          | 0.91 (0.54, 1.52) | 0.718 | 0.64 (0.34, 1.20) | 0.165 |
| P for trend    |                | 0.803      |           | 0.322 |
| Categories     |                |            |           |
| <7.6           | 80/82          | Ref.       | Ref.      |
| ≥7.6           | 244/242        | 1.04 (0.70, 1.56) | 0.838 | 0.88 (0.55, 1.40) | 0.591 |
| Ischemic stroke|                |            |           |
| Per SD increment | 254/254       | 1.04 (0.84, 1.28) | 0.716 | 0.91 (0.70, 1.19) | 0.487 |
| Quartiles      |                |            |           |
| Q1 (<7.6)      | 62/65          | Ref.       | Ref.      |
| Q2 (7.6–<9.6)  | 54/73          | 0.82 (0.49, 1.37) | 0.449 | 0.81 (0.44, 1.47) | 0.485 |
| Q3 (9.6–<11.9) | 76/51          | 1.59 (0.93, 2.73) | 0.093 | 1.32 (0.68, 2.56) | 0.406 |
| Q4 (≥11.9)     | 62/65          | 1.06 (0.60, 1.95) | 0.797 | 0.75 (0.35, 1.57) | 0.440 |
| P for trend    |                | 0.300      |           | 0.796 |
| Categories     |                |            |           |
| <7.6           | 62/65          | Ref.       | Ref.      |
| ≥7.6           | 192/189        | 1.08 (0.69, 1.70) | 0.729 | 0.94 (0.54, 1.62) | 0.815 |
| Hemorrhagic stroke|             |            |           |
| Per SD increment | 69/69          | 0.90 (0.61, 1.34) | 0.610 | 1.10 (0.64, 1.87) | 0.738 |
| Quartiles      |                |            |           |
| Q1 (<7.7)      | 17/18          | Ref.       | Ref.      |
| Q2 (7.7–<9.3)  | 20/14          | 1.51 (0.53, 4.33) | 0.439 | 1.77 (0.47, 6.56) | 0.396 |
| Q3 (9.3–<12.2) | 17/17          | 1.02 (0.34, 3.04) | 0.975 | 1.35 (0.31, 5.85) | 0.688 |
| Q4 (≥12.2)     | 15/20          | 0.76 (0.25, 2.31) | 0.625 | 0.96 (0.22, 4.19) | 0.965 |
| P for trend    |                | 0.430      |           | 0.734 |
| Categories     |                |            |           |
| <7.7           | 17/18          | Ref.       | Ref.      |
| ≥7.7           | 52/51          | 1.11 (0.45, 2.73) | 0.819 | 1.43 (0.43, 4.74) | 0.557 |

*Adjusted for body mass index (BMI), smoking status, alcohol drinking, systolic blood pressure (SBP) at baseline, fasting blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), total homocysteine (tHcy), folate, as well as estimated glomerular filtration rate (eGFR) at baseline.

in childhood and continues into adulthood (31–33); (2) the low incidence of first stroke in women may have weakened the statistical power of the current study. Overall, the exact mechanisms underlying the sex difference in the association between plasma vitamin E levels and the risk of first stroke remain to be understood.

Third, we found that among males, alcohol drinking was a significant effect modifier. A stronger association between vitamin E and first stroke was found in non-drinkers. The EPIC-CVD case-cohort study found that alcohol intake was positively associated with the risk of different stroke subtypes (34). Consistently, in the prospective China Kadoorie Biobank, genotype-predicted mean alcohol intake had a continuously positive log-linear association with the risk of intracerebral hemorrhage and ischaemic stroke (35). Mechanisms linking alcohol drinking and first stroke risk remain incompletely understood; however, available evidence suggests that alcohol drinking may induce oxidative stress and vascular injury (36–38). Consistently, alpha-tocopherol (alpha-TOH) has also been suggested as a pro-oxidant (21). Of note, in our current study, the lowest first stroke risk was found in non-drinking males with low vitamin E levels, and similar first stroke risks were observed in current drinking males and/or those with high vitamin E levels. Therefore, we speculate that alcohol drinking and high vitamin E levels may share some common pathway in the development of first stroke. As such, the detrimental effects of alcohol drinking may attenuate the positive relation of plasma vitamin E and first stroke. However, more
FIGURE 2 | Association between plasma vitamin E (<quartile 1 vs. ≥quartile 1) and risk of first total stroke among males in various subgroups. Each subgroup analysis adjusted, if not stratified, for age, treatment group, study site, body mass index (BMI), smoking status, alcohol drinking, systolic blood pressure at baseline (SBP), fasting blood glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), total homocysteine (tHcy), folate, as well as estimated glomerular filtration rate (eGFR) at baseline.

| Variables                              | < Quartile 1 | ≥ Quartile 1 | OR(95%CI) | P for interaction |
|----------------------------------------|--------------|--------------|-----------|-------------------|
| Age, years                             |              |              |           |                   |
| <65                                    | 41/43        | 129/127      | 1.38(0.74,2.58) | 0.241             |
| ≥65                                    | 25/38        | 99/86        | 1.81(0.94,3.46) | 0.568             |
| Treatment Group                        |              |              |           |                   |
| Enalapril                              | 42/51        | 133/124      | 1.40(0.79,2.49) | 0.676             |
| Enalapril-folic acid                   | 24/30        | 95/89        | 1.67(0.78,3.56) |                   |
| BMI, kg/m²                             |              |              |           |                   |
| <24.1(median)                          | 30/45        | 108/111      | 1.72(0.88,3.37) | 0.450             |
| ≥24.1                                 | 36/36        | 120/102      | 1.32(0.71,2.45) |                   |
| Baseline SBP, mmHg                     |              |              |           |                   |
| <160                                   | 15/32        | 45/90        | 0.96(0.40,2.30) | 0.549             |
| ≥160                                   | 51/49        | 183/123      | 1.52(0.91,2.54) |                   |
| Current smoking                        |              |              |           |                   |
| No                                     | 26/36        | 101/107      | 1.18(0.59,2.36) | 0.008             |
| Yes                                    | 40/45        | 127/106      | 1.72(0.95,3.10) |                   |
| Current alcohol drinking               |              |              |           |                   |
| No                                     | 32/53        | 114/104      | 2.64(1.41,4.96) |                   |
| Yes                                    | 34/28        | 114/109      | 0.84(0.43,1.66) |                   |
| Total cholesterol, mmol/L              |              |              |           |                   |
| <5.2                                   | 30/49        | 78/81        | 2.07(1.05,4.08) | 0.235             |
| ≥5.2                                   | 32/30        | 143/127      | 1.29(0.70,2.39) |                   |
| Total-Homocysteine, µmol/L             |              |              |           |                   |
| <14.6(median)                          | 25/38        | 110/113      | 1.80(0.92,3.52) | 0.707             |
| ≥14.6                                  | 37/41        | 112/96       | 1.55(0.83,2.88) |                   |
| Fasting glucose, mmol/L                |              |              |           |                   |
| <6.1                                   | 43/59        | 152/153      | 1.64(0.97,2.77) | 0.531             |
| ≥6.1 or diabetes                       | 19/20        | 70/55        | 1.15(0.47,2.82) |                   |

research is needed to validate our findings, and explore its underlying mechanisms.

**STRENGTHS AND LIMITATIONS**

Our study had high quality baseline and follow-up epidemiological and clinical data including validation of incident stroke cases, and a comprehensive analysis of many important risk factors or confounders of stroke. However, there are also several limitations of the current study. First, although the current study’s mean ± SD vitamin E level (9.4 ± 3.6 µg/mL in male and 10.0 ± 3.5 µg/mL in female) seemed to be comparable with other nested case-control studies (31–34), the generalizability of our findings to other populations with different demographic and clinical characteristics requires caution. Second, our analyses are based on a single baseline
measurement of vitamin E and therefore may not reflect levels over a longer period. Third, our study only measured α-tocopherol in plasma and could therefore not specify the levels of other different chemical forms of vitamin E (e.g., γ-tocopherol and tocotrienol). Fourth, we did not have detailed dietary information, and could not adjust quality of diet in the regress models. Finally, there is an inherit limitation of any post-hoc analysis; we cannot exclude the possibility of residual confounding despite our control of important epidemiologic and clinical covariates in the analyses. Additional studies are required to confirm our results.

CONCLUSIONS

In Chinese hypertensive patients, higher baseline plasma vitamin E was significantly associated with an increased risk of first stroke in males. Our findings, if further confirmed, may inform clinical and nutritional guidelines on the primary prevention of stroke, by including plasma vitamin E as a potentially modifiable risk factor, especially in hypertensive males. However, more studies are needed to verify our results and to further examine the biological mechanisms underlying the associations.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China. The studies were conducted in accordance with the guidelines and regulations of the Ethics Committee of the Institute of Biomedicine. All subjects/participants provided their written informed consent to participate in this study.

REFERENCES

1. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi Nn, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: A systematic analysis for the global burden of disease study 2017. Lancet. (2018) 392:1736–88. doi: 10.1016/S0140-6736(18)32203-7
2. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. (2014) 45:3754–832. doi: 10.1161/STR.000000000000046
3. David Spence J. Advances in stroke prevention. J Transl Int Med. (2018) 6:105–14. doi: 10.2478/jtim-2018-0024
4. Clarke MW, Burnett JR, Croft KD. Vitamin E in human health and disease. Crit Rev Clin Lab Sci. (2008) 45:417–50. doi: 10.1080/10408360802118625
5. Saldeen T, Li D, Mehta JL. Differential effects of alpha- and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol. (1999) 34:1208–15. doi: 10.1016/S0735-1097(99)00333-2
6. Liu M, Wallmon A, Olson-Mortlock C, Wallin R, Saldeen T. Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. Am J Clin Nutr. (2003) 77:700–6. doi: 10.1093/ajcn/77.3.700
7. Kubota Y, Iso H, Date C, Kikuchi S, Watanabe Y, Wada Y, et al. Dietary intakes of antioxidant vitamins and mortality from cardiovascular disease: the Japan collaborative cohort study (JACC) study. Stroke. (2011) 42:1665–72. doi: 10.1161/STROKEAHA.110.601526
8. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke subtypes: Meta-analysis of randomised controlled trials. BMJ. (2010) 341:c5702. doi: 10.1136/bmj.c5702
9. Bin Q, Hu X, Cao Y, Gao F. The role of vitamin E (tocopherol) supplementation in the prevention of stroke. A meta-analysis of 13 randomised controlled trials. Thromb Haemost. (2011) 105:579–85. doi: 10.1160/TH10-11-0729
10. Cheng P, Wang L, Ning S, Liu Z, Lin H, Chen S, et al. Vitamin E intake and risk of stroke: a meta-analysis. Br J Nutr. (2018) 120:1181–8. doi: 10.1017/S0007114518002647
11. Loh HC, Lim R, Lee KW, Ooi CY, Chuan DR, Loi I, et al. Effects of vitamin E on stroke: a systematic review with meta-analysis and trial sequential analysis. Stroke Vasc Neurol. (2021) 6:109–20. doi: 10.1136/svn-2020-000519
12. Brigelsius-Flodh R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM, Azzi A. The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr. (2003) 77:763S–16. doi: 10.1093/ajcn/76.4.703
13. Benzies JF, Janus ED, Strain JI. Plasma ascorbate and vitamin E levels in Hong Kong Chinese. Eur J Clin Nutr. (1998) 52:447–51. doi: 10.1038/sj.ejcn.1600586

AUTHOR CONTRIBUTIONS

XX, XQ, YS, LL, and HZ: study concept and design. XQ, YS, JinL, LL, HZ, BX, TL, ZZ, PC, YL, BW, JiaL, YZ, CL, YH, and FR: conduct of study. YS, JinL, LL, and TL: data collection and analysis. XQ, YS, JinL, LL, and RX: drafting of the manuscript. XQ, YS, JinL, LL, HZ, ZZ, PC, YL, XH, BW, JL, YZ, CL, YH, and FR: critical review and revision of the manuscript for important intellectual content. All authors contributed to the article and approved the submitted version.

FUNDING

The study was supported by the National Key Research and Development Program (2016YFE00205400, 2018ZX09739010, and 2018ZX09301034003), the Department of Science and Technology of Guangdong Province (2020B121202010), the Science and Technology Planning Project of Guangzhou, China, (201707020010), the Science, Technology and Innovation Committee of Shenzhen (GJHS20170314114526143, JSGG20180703155802047), and the Economic, Trade and Information Commission of Shenzhen Municipality (20170505161556110, 20170505160926390, and 201705051617070).

ACKNOWLEDGMENTS

We thank the investigators and participants of the China Stroke Primary Prevention Trial (CSPPT), the parent study, who made this report possible.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2021.734580/full#supplementary-material
14. Uesugi S, Ishihara J, Iso H, Sawada N, Takachi R, Inoue M, et al. Dietary intake of antioxidant vitamins and risk of stroke: the Japan public health center-based prospective study. *Eur J Clin Nutr.* (2017) 71:1179–85. doi: 10.1038/ejcn.2017.71

15. Nagao M, Moriyama Y, Yamagishi K, Iso H, Tamakoshi A, IACC Study Group. Relation of serum α- and γ-tocopherol levels to cardiovascular disease-related mortality among Japanese men and women. *J Epidemiol.* (2012) 22:402–10. doi: 10.2188/jea.JE20120002

16. Hak AE, Ma J, Powell CB, Campos H, Gaziano JM, Willett WC, et al. Prospective study of plasma carotenoids and tocopherols in relation to risk of ischemic stroke. *Stroke.* (2004) 35:1584–8. doi: 10.1161/01.STR.0000132197.67350.bd

17. Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the cspt randomized clinical trial. *JAMA.* (2015) 313:1325–35. doi: 10.1001/jama.2015.2274

18. Kong X, Huang X, Zhao M, Xu B, Xu R, Song Y, et al. Platelet count affects efficacy of folic acid in preventing first stroke. *J Am Coll Cardiol.* (2018) 71:2136–46. doi: 10.1016/j.jacc.2018.02.072

19. Qin X, Li Y, He M, Tang G, Yin D, Liang M, et al. Folic acid therapy reduces serum uric acid in hypertensive patients: a subsity of the china stroke primary prevention trial (CSPTT). *Am J Clin Nutr.* (2017) 105:882–9. doi: 10.9345/jac.2016.143.1131

20. Qin X, Li J, Zhang Y, Ma W, Fan F, Wang B, et al. Prevalence and associated factors of diabetes and impaired fasting glucose in Chinese hypertensive adults aged 45 to 75 years. *PLoS ONE.* (2012) 7:e42538. doi: 10.1371/journal.pone.0042538

21. Song Y, Xu B, Xu R, Tung R, Frank E, Tromble W, et al. Independent and joint effect of brachial-ankle pulse wave velocity and blood pressure control on incident stroke in hypertensive adults. *Hypertension.* (2016) 68:46–53. doi: 10.1161/HYPERTENSIONAHA.115.07023

22. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Brahat LT, Chaturvedi N, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the american heart association/american stroke association. *Circulation.* (2011) 124:1951–7. doi: 10.1161/CIR.0b013e31820f1c40

23. Zuo W, Jiang S, Guo Z, Feldman MW, Tuljapurkar S, et al. Prospective study of plasma carotenoids and tocopherols with lower total and cause-specific mortality in the alpha-tocopherol, beta-carotene cancer prevention study. *Am J Clin Nutr.* (2006) 84:1200–7. doi: 10.9345/ajcn.84.5.1200

24. Roberts HJ. Perspective on vitamin E as therapy. *JAMA.* (1981) 246:129–31. doi: 10.1001/jama.246.4.1239

25. Bowry VW, Mohr D, Cleary J, Stocker R. Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipoprotein. *J Biol Chem.* (1995) 270:5756–63. doi: 10.1074/jbc.270.11.5756

26. Witting PK, Bowry VW, Stocker R. Inverse deuterium kinetic isotope effect for peroxidation in human low-density lipoprotein (Idl): a simple test for tocopherol-mediated peroxidation of Idl lipids. *FEBS Lett.* (1995) 375:45–9. doi: 10.1016/0014-5793(95)01172-B

27. Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. *Biochem J.* (1992) 288:341–4. doi: 10.1042/bj2880341

28. Stanhewicz AE, Wenner MM, Stachenfeld NS. Sex differences in endothelial function important to vascular health and overall cardiovascular disease risk across the lifespan. *Am J Physiol Heart Circ Physiol.* (2018) 315:H1569–88. doi: 10.1152/ajpheart.00396.2018

29. Khalil RA. Sex hormones as potential modulators of vascular function in hypertension. *Hypertension.* (2005) 46:249–54. doi: 10.1161/01.HYP.0000172945.06681.a4

30. Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular disease in women: Clinical perspectives. *Circ Res.* (2016) 118:1273–93. doi: 10.1161/CIRCRESAHA.116.307547

31. Ricci C, Wood A, Muller D, Gunter MJ, Agudo A, Boeing H, et al. Alcohol intake in relation to non-fatal and fatal coronary heart disease and stroke: EPIC-CVD case-cohort study. *BMJ.* (2018) 361:k934. doi: 10.1136/bmj.k934

32. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. *Lancet.* (2019) 393:1831–42. doi: 10.1016/S0140-6736(18)31772-0

33. Costanzo S, Di Castelnuovo A, Donati MB, Iacoviello L, de Gaetoan G. Cardiovascular and overall mortality risk in relation to alcohol consumption in patients with cardiovascular disease. *Circulation.* (2010) 121:1951–9. doi: 10.1161/CIRCULATIONAHA.109.865840

34. Sesso HD, Cook NR, Buring JE, Manson JE, Gaziano JM. Alcohol consumption and the risk of hypertension in women and men. *Hypertension.* (2008) 51:1080–7. doi: 10.1161/HYPERTENSIONAHA.107.104968

35. Mostofsky E, Chahal HS, Mukamal KJ, Rimm EB, Mittelman MA. Alcohol and immediate risk of cardiovascular events: a systematic review and dose-response meta-analysis. *Circulation.* (2016) 133:979–87. doi: 10.1161/CIRCULATIONAHA.115.019743

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Song, Li, Liu, Xu, Zhou, Xu, Lin, Chen, Li, Liu, Huang, Wang, Zhang, Li, Huo, Ren, Xu, Zhang and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.